Request Demo
Last update 26 Dec 2024
ZG-006
Last update 26 Dec 2024
Overview
Basic Info
Drug Type Trispecific T-cell engager (TriTE) |
Synonyms ZG 006, ZG-006, ZG006 |
Target |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), DLL3 inhibitors(Delta-like protein 3 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Login to view timeline
Related
7
Clinical Trials associated with ZG-006NCT06592638
A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Patients with Small Cell Lung Cancer
NCT06283719
A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
NCT06440057
A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
100 Clinical Results associated with ZG-006
Login to view more data
100 Translational Medicine associated with ZG-006
Login to view more data
100 Patents (Medical) associated with ZG-006
Login to view more data
100 Deals associated with ZG-006
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Neuroendocrine Carcinoma | Phase 2 | CN | 12 Aug 2024 | |
| Advanced Lung Small Cell Carcinoma | Phase 2 | CN | 19 Oct 2023 | |
| Small Cell Lung Cancer | IND Application | US | 10 Apr 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 24 | lbjkxswhak(dbxjwxsgkf) = 绝大多数治疗相关不良事件（TRAEs）的严重程度为1级或2级。最常见的TRAEs为发热、贫血和细胞因子释放综合征（CRS，3级CRS 1例）。 jicqxfaugd (mrrbmxwjtu ) View more | Positive | 25 Sep 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free